CONTEXT THERAPEUTICS INC (CNTX)
US21077P1084 - Common Stock
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x...
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Context Therapeutics to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and...
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. ...
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents...
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager...
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight
If you believe in chasing the winners higher, here are three hypergrowth stocks that may provide Nvidia-like gains.
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024
CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Context Therapeutics (NASDAQ:CNTX) just reported results for the first quarter ...
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 ...
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 ...
Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development...
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Context Therapeutics (NASDAQ:CNTX) just reported results for the fourth quarter...
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash...